Amphastar Pharmaceuticals Income After Taxes 2012-2025 | AMPH
Amphastar Pharmaceuticals income after taxes from 2012 to 2025. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Amphastar Pharmaceuticals Annual Income After Taxes
(Millions of US $) |
| 2024 |
$160 |
| 2023 |
$140 |
| 2022 |
$93 |
| 2021 |
$64 |
| 2020 |
$1 |
| 2019 |
$47 |
| 2018 |
$-7 |
| 2017 |
$4 |
| 2016 |
$10 |
| 2015 |
$-3 |
| 2014 |
$-11 |
| 2013 |
$12 |
| 2012 |
$18 |
| 2011 |
$8 |
| 2009 |
$23 |
Amphastar Pharmaceuticals Quarterly Income After Taxes
(Millions of US $) |
| 2025-03-31 |
$25 |
| 2024-12-31 |
$38 |
| 2024-09-30 |
$40 |
| 2024-06-30 |
$38 |
| 2024-03-31 |
$44 |
| 2023-12-31 |
$37 |
| 2023-09-30 |
$50 |
| 2023-06-30 |
$26 |
| 2023-03-31 |
$27 |
| 2022-12-31 |
$34 |
| 2022-09-30 |
$16 |
| 2022-06-30 |
$18 |
| 2022-03-31 |
$25 |
| 2021-12-31 |
$20 |
| 2021-09-30 |
$31 |
| 2021-06-30 |
$9 |
| 2021-03-31 |
$4 |
| 2020-12-31 |
$-6 |
| 2020-09-30 |
$5 |
| 2020-06-30 |
$-1 |
| 2020-03-31 |
$4 |
| 2019-12-31 |
$1 |
| 2019-09-30 |
$1 |
| 2019-06-30 |
$47 |
| 2019-03-31 |
$-2 |
| 2018-12-31 |
$2 |
| 2018-09-30 |
$2 |
| 2018-06-30 |
$-3 |
| 2018-03-31 |
$-7 |
| 2017-12-31 |
$1 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$2 |
| 2017-03-31 |
$1 |
| 2016-12-31 |
$-3 |
| 2016-09-30 |
$4 |
| 2016-06-30 |
$7 |
| 2016-03-31 |
$2 |
| 2015-12-31 |
$8 |
| 2015-09-30 |
$-3 |
| 2015-06-30 |
$-7 |
| 2015-03-31 |
$-1 |
| 2014-12-31 |
$-3 |
| 2014-09-30 |
$-5 |
| 2014-06-30 |
$-1 |
| 2014-03-31 |
$-2 |
| 2013-12-31 |
$2 |
| 2013-09-30 |
$0 |
| 2013-06-30 |
$8 |
| 2013-03-31 |
$2 |
| 2012-12-31 |
$52 |
| 2012-09-30 |
$57 |
| 2012-06-30 |
$49 |
| 2012-03-31 |
$46 |
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.181B |
$0.732B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
